Skip to main content
. 2024 Aug 24;16(17):2953. doi: 10.3390/cancers16172953

Figure 3.

Figure 3

Figure 3

The sialyltransferase inhibitor P-SiaFNEtoc blocks α2,6 sialylation in the VCaPEnzR and LNCaPEnzR prostate cancer cells. (A) Detection of immunofluorescent staining of ST6GAL1 and α2,6-sialylation of N-glycans in the VCaP control and VCaPEnzR cells treated with 20 µM of the sialyltransferase inhibitor P-SiaFNEtoc for 6 days. Treatment of both cell lines with P-SiaFNEtoc inhibits α2,6-sialylation of N-glycans (detected using SNA lectin). Control cells were treated with DMSO. Scale bar = 50 µm. The images are representative of three biological repeats. (B) Detection of immunofluorescent staining of ST6GAL1 and α2,6-sialylation of N-glycans in LNCaP control and LNCaPEnzR cells treated with 2 µM of the sialyltransferase inhibitor P-SiaFNEtoc for 3 days. Treatment of both cell lines with P-SiaFNEtoc inhibits α2,6-sialylation of N-glycans (detected using SNA lectin). The control cells were treated with DMSO. Scale bar = 50 µm. The images are representative of three biological repeats.